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http:WHAT THIS PAPER ADDS
Although patient-reported outcome measures are frequently recorded in patients with peripheral arterial dis-
ease (PAD) to determine the statistical signiﬁcance of change in quality of life as a measure of effectiveness of
treatment, the interpretation of the clinical relevance of change may be difﬁcult. This is the ﬁrst study to
illustrate the concept of minimally important difference to deﬁne clinically important changes rather than
statistically signiﬁcant changes in PAD patients.Objective: Interpreting whether changes in quality of life (Qol) in patients with peripheral arterial disease (PAD)
are not only statistically signiﬁcant but also clinically relevant, may be difﬁcult. This study introduces the concept
of the minimally important difference (MID) to vascular surgeons using Qol outcomes of patients treated for
chronic critical limb ischemia (CLI).
Methods: The Vascular Quality of Life (VascuQol) questionnaire was recorded at baseline before treatment and
after 6 months follow-up in consecutive patients with CLI treated between May 2007 and May 2010. Statistical
signiﬁcance of change in VascuQol score was tested with the Wilcoxon Signed Rank test. The MID for the
VascuQol score was determined using a clinical anchor-based method and a distribution-based method.
Results: A total of 127 patients with CLI completed the VascuQol after 6 months. The VascuQol sum scores
improved from 3.0 (range 1.1e5.9) at baseline to 4.0 (range 1.2e6.7) at 6 months (p < .001). The MID on the
VascuQol sumscore indicating a clinically important change determined with the anchor-based method was 0.36,
and with the distribution-based method was 0.48. On an individual level, depending on the method of
determining the MID, this resulted in 60% to 68% of the patients with an important beneﬁt.
Conclusions: Expression of changes in Qol by means of the MID provides better insight into clinically important
changes than statistical signiﬁcance.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Traditionally, the effectiveness of therapies in patients with
peripheral arterial disease is expressed in easy to measure
“hard endpoints” such as (bypass) patency or limb salvage.
Yet, the level of functioning or quality of life may matter
more to the patient than the patency of a bypass. This has
been recognized by the vascular surgery community and has
resulted in an increasing interest in patient-reportedTo access continuing medical education questions on this pa-
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//dx.doi.org/10.1016/j.ejvs.2013.10.012outcomes (PRO) in research.1e3 The most commonly used
instruments in patients with peripheral arterial disease (PAD)
include generic quality of life (Qol) questionnaires, such as the
Short Form-36 (SF-36) and disease speciﬁc Qol question-
naires, such as the Vascular Quality of Life questionnaire
(VascuQol).4e6 Both instruments rate the patient’s quality of
life on a numerical scale, and differences in scores can be used
to evaluate the effectiveness of therapies. The interpretation
of scores on these questionnaires is hampered by the lackof a
deﬁnition as towhat amount of change or difference in scores
constitutes a clinically meaningful change or difference. For
example, is a statistically signiﬁcantmean change of 0.44 from
the baseline score sufﬁcient for an individual patient?
The concept of the minimally important difference (MID)
was developed to better express clinically important beneﬁt
or deterioration rather than just statistically signiﬁcant dif-
ferences or changes in PRO scores.7 The MID can be
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that is important to patients. Approaches to estimate the
MID have been classiﬁed as either anchor-based or
distribution-based.8,9 Anchor-based methods compare Qol
scores with another measurement, such as a patient rated
global change question, and distribution-based methods
build on the variability of the Qol scores.
In this paper we want to introduce the concept of theMID
to vascular surgeons using Qol outcomes of patients treated
for chronic critical limb ischemia (CLI) as an example by
applying anchor-based and distribution-based approaches.
MATERIAL AND METHODS
Study population
Between May 2007 and May 2010 we conducted a pro-
spective observational cohort study in which we included all
consecutive patients with chronic CLI, who visited our
vascular surgery department, and gave written informed
consent to participate. Chronic CLI was deﬁned as Fontaine
stage III or IV with symptoms present for more than 2
weeks. Patients with insufﬁcient knowledge of the Dutch
language, an estimated life expectancy of less than 6
months or unable to give informed consent were excluded.
The study was approved by the local medical ethical
committee.Treatment
Patients received treatment as agreed with their vascular sur-
geon independent of the study. Endovascular revascularization
when possible is the ﬁrst line treatment in our institution.
Patients were treated with revascularization (endovascular or
surgical), primary major amputation, or conservative treat-
ment. Endovascular revascularization included both percuta-
neous transluminal angioplasty (PTA) and percutaneous
subintimal angioplasty (SA), with or without stent placement.
Surgical revascularization included both bypass surgery and
endarterectomy. Assessment of patency, limb salvage, or
comparison of outcomes between endovascular or surgical
revascularization was not the aim of this study.Assessments
History. At baseline before treatment we recorded patient
demographics (sex, age, body mass index [BMI]), risk factors
for atherosclerosis (diabetes mellitus, hypertension, smok-
ing, renal failure, hypercholesterolemia, history of coronary
heart disease, history of stroke, family history of cardio-
vascular disease, history of vascular interventions [endo-
vascular and surgical]), and major contralateral amputation.
VascuQol. All patients completed the disease-speciﬁc Vas-
cuQol questionnaire at baseline before treatment and again
at 6 months follow-up. The VascuQol is a sumscore-based
instrument and consists of 25 items on ﬁve domains, that
is Pain (4 items), Activity (8), Emotional (7), Symptoms (4),
and Social (2). Each item is rated on a seven point response
scale, with a score of one being the worst and a score ofseven the best possible. The total average sumscore is the
sum of all 25 item scores divided by 25. For each separate
domain an average score can be calculated (sum of all items
of one domain divided by the number of items of that
domain). So, both the overall score and the scores per
domain range from one to seven. The VascuQol has shown
to be a reliable and valid instrument for assessment of Qol
in patients with PAD.4 The VascuQol was sent by postal mail
and completed by the patients at home.Analysis of treatment effect on quality of life
Traditional approach. Differences between VascuQol scores
at baseline and at 6 months were assessed using a
paired Student t test (normally distributed data) or the
Wilcoxon Signed Ranks test (non-normally distributed data)
where appropriate. A p value <.05 indicated statistical
signiﬁcance.
Minimally important difference. It is currently recom-
mended that estimation of a MID for a speciﬁc PRO in-
strument should be based on multiple approaches.10
Anchor-based approach. The anchor-based approach re-
quires the use of an independent, objective criterion to
determine a threshold value for the MID, such as a clinical
measure or a patient-rated global change question. This can
be done, for example, by asking the patient whether the
clinical status has deteriorated, is unchanged, or has
improved. There are several approaches to using a clinical
anchor to determine the MID. One method is to deﬁne the
MID as the average change in score between patients rating
themselves as improved minus the average change in pa-
tients rating their status as unchanged. In another approach
the MID is deﬁned as the average change in patients who
improve. A third method to deﬁne the MID is to calculate
the 95% conﬁdence interval (CI) of the average change in
PRO in patients who rate themselves as unchanged. The
upper and lower limits of the 95% CI is the MID.7,8
In our study, we used the ﬁrst approach by relating the
average VascuQol score changes to the change in Fontaine
classiﬁcation as an anchor to estimate the MID.11 The change
in Fontaine classiﬁcationwas deﬁned according to the change
in patient reported symptoms of PAD at the 6-month follow-
up visit.The change in Fontaine classiﬁcationwas rated byone
of the investigators (FAF or RM) at the 6-month follow-up visit
on a four point scale (much improved e improved e un-
changed e worse) (Appendix I). According to Revicki and
Cohen, theMID should be based on a patient-based or clinical
anchor that has a correlation 0.30 with the PRO instru-
ment.11,12 Therefore correlation coefﬁcients (Pearson or
Spearman’s Rankwhen appropriate)were calculated between
the change in VascuQol sumscore and the change in Fontaine
classiﬁcation between baseline and 6 months follow-up.
First, for each category (much improved e improved e
unchangedeworse) themean change in VascuQol sumscore
was calculated. Then the MID for improvement and the MID
for deterioration was calculated as the difference between
the mean change in VascuQol sumscore of the improved or
Figure 1. Minimally important difference.
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sumscore of the unchanged patients. Finally, the overall MID
was calculated as the sum of mean MID divided by 2.
Next, the MID was added or subtracted from the baseline
VascuQol sumscore of each individual patient, which gives a
sumscore range. This baseline range score was compared
with the 6-month VascuQol score of each individual patient.
If the 6-month score was within the baseline range score,
this meant an unimportant beneﬁt or deterioration. If the 6-
month score was beyond the baseline range score, this
meant an important beneﬁt or deterioration. This allowed
us to calculate proportions of patients with an important
beneﬁt or deterioration and with an unimportant beneﬁt or
deterioration.
Distribution-based approach. A distribution-based approach
focuses on the statistical characteristics of a patient sample,
and then compares an observed change with an index of
variability to determine whether the change is substantial
and clinically meaningful. Such an approach has been uti-
lized for a variety of measures of statistical variability,
including the standard error of measurement, the standard
error of mean change, the standard deviation of change,
and the standard deviation of the sample group. The reader
is referred to Copay and colleagues for a more compre-
hensive overview of these two approaches.8 Previous
research has shown that changes in PRO scores of half a
standard deviation constitute at least a clinically signiﬁcant
change.8,9 Therefore, we considered half a standard devia-
tion of the baseline score to be a clinically important change
in Qol (MID threshold) based on the universality theory of
Norman et al.9
First, the mean baseline score (SD) was calculated for
the total group. Second, half of the SD was added or sub-
tracted from the baseline score of each individual patient,
giving a range of VascuQol sumscores. This baseline range
score was compared with the 6-month VascuQol score of
each individual patient. If the 6-month score was within the
baseline range score, this meant an unimportant beneﬁt orFigure 1a. Flow diadeterioration. If the 6-month score was beyond the baseline
range score, this meant an important beneﬁt or deteriora-
tion. This allowed us to calculate proportions of patients
with an important beneﬁt or deterioration and with an
unimportant beneﬁt or deterioration. Fig. 1 is a graphical
representation of this MID concept.
RESULTS
One-hundred and ﬁfty out of 218 eligible patients referred
between May 2007 and May 2010 were included. Sixty-
eight patients did not participate in this study because
of cognitive impairment, insufﬁcient knowledge of the
Dutch language (excluded patients), or the eventual burden
to attend the follow-up visit (patients who withdrew con-
sent) (Fig. 1a). One-hundred and twenty-seven patients
completed the VascuQol at baseline and 6 months. The
initial treatments were endovascular (n ¼ 64; 50.4%), sur-
gical (n ¼ 44; 34.6%), conservative (n ¼ 7; 6%), or a major
amputation (n ¼ 12; 9.4%). Baseline characteristics are
described in Table 1.gram of study.
Table 1. Baseline characteristics.
Demographics Baselinea
(n ¼ 127)
Patient characteristics, mean (SD)
Age, year 67.0 (12.4)
BMI 25.8 (4.8)
Patient characteristics, number
(percentage)
Male 82 (65%)
Diabetes mellitus 53 (42%)
Hypertension 99 (78%)
Hyperlipidemia
No 59 (46%)
Yes 21 (17%)
Unknown 47 (37%)
Smoking
Current 46 (36%)
Former 57 (45%)
Never 22 (17%)
Coronary heart disease 49 (39%)
COPD 28 (22%)
Previous TIA or stroke 29 (23%)
Positive family historyb 65 (51%)
Renal failurec 19 (15%)
Previous treatment, number (percentage)
Ipsilateral revascularizationd 47 (37%)
Contralateral major amputation 6 (5%)
Fontaine stage
Fontaine III 37 (29%)
Fontaine IV 90 (71%)
Ambulation
Level of walking at presentation
Inside and outside 82 (65%)
Only inside 36 (28%)
Wheel chair bonded or bedridden 9 (7%)
Residential status
Independent 117 (92%)
Dependent 10 (8%)
Self reported walking distances, number (percentage)
PFWD 0 m 66 (52%)
MWD < 10 m 32 (25%)
Examinations symptomatic extremity, median (range)
Ankle Brachial Pressure Index 0.46 (0.19e1.11)
Absolute toe pressure 30 (10e110)
Absolute TcO2 22 (1e48)
VascuQol baseline scores, median (range)
Sumscore 3.0 (1.1e5.9)
Activity 2.4 (1.0e6.6)
Symptoms 3.3 (1.0e7.0)
Pain 2.3 (1.0e7.0)
Emotional 3.5 (1.0e6.9)
Social 3.0 (1.0e7.0)
BMI ¼ body mass index; COPD ¼ chronic obstructive pulmonary
disease; TIA ¼ transient ischemic attack; PFWD ¼ Pain Free
Walking Distance; MWD ¼ Maximum Walking Distance;
TcO2 ¼ transcutaneous oxygen pressure; VascuQol ¼ Vascular
Quality of Life questionnaire.
a Baseline, before intervention.
b For cardiovascular disease.
c Renal failure was deﬁned as serum creatinine >220 mmol/L.
d Surgical or endovascular.
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The VascuQol scores at baseline and 6 months were non-
normally distributed. At baseline, the median VascuQol
sumscore of the 127 patients was 3.0. The median baseline
VascuQol sumscore improved with 1 point from 3.0 (range
1.1e5.9) to 4.0 (range 1.2e6.7) at 6 months. This
improvement was statistically signiﬁcant (p < .001).Anchor-based approach
We found that the change in Fontaine classiﬁcation was
signiﬁcantly correlated to the 6-month VascuQol sumscore
(rspearman ¼ .51; p ¼ .000), implying that this anchor fulﬁlled
the criteria of Revicki.11
The mean change in VascuQol sumscore in patients with
unchanged symptoms of PAD was 0.34 points (Table 2). The
mean change in improved patients was 0.69; resulting in a
MID for improvement of 0.69e0.34 ¼ 0.35. The mean
change in deteriorated (worse) patients was 0.03, result-
ing in a MID for deterioration of 0.34  0.03 ¼ 0.37 (see
Table 2). Thus, the MID for improvement was 0.35 points,
and the MID for deterioration was 0.37. Consequently, the
overall MID was 0.36 (0.35 þ 0.37/2).Distribution-based approach
The mean (SD) VascuQol sumscore at baseline was 3.04
(0.97). Thus, the MID for each individual patient was
baseline VascuQol score  0.48 (i.e. 0.97/2).
Fig. 2 shows the proportion of the 127 patients with an
(un)important beneﬁt or deterioration according to the
distribution-based approach (MID ¼ half a SD ¼ 0.48)
and the anchor-based approach (MID ¼ 0.36). On an in-
dividual level, depending on the MID approach, 60% to 68%
of the patients showed an important beneﬁt.
DISCUSSION
The idea of a MID was introduced in the literature, when
Jaeschke et al. attempted to estimate how much of a dif-
ference in scores on an asthma Qol questionnaire would
result in some change in clinical management that is to be
considered clinically meaningful.13 The concept of a “clini-
cally important difference” has evolved as a way to over-
come the shortcomings of the “statistically signiﬁcant
difference”.8 Although there is no consensus as to the su-
perior method to determine the MID, it is recommended
that the MID is primarily based on relevant patient-based
and clinical anchors. Distribution-based methods should
be used to support the estimates from anchor-based ap-
proaches and can be used in situations where anchor-based
estimates are unavailable.11
Our study is an example of how to determine the MID
for the VascuQol in patients treated for CLI using both
anchor-based and distribution-based methods. The MID
based on the anchor-based approach was lower than the
MID determined with the distribution-based approach
(0.36 vs. 0.48). This ﬁnding is consistent with previously
published literature, showing that half a standard
Table 2. Categorizing change in VascuQol sumscore by global rating of change.
Change in Fontaine classiﬁcation
Worse Fontaine classiﬁcation changed from 3 to 4, or
patients with Fontaine 4 developed more ulcers
or gangrene
Unchanged Fontaine classiﬁcation did not change and for
patients with Fontaine 4, number of ulcers did
not change
Improved Fontaine classiﬁcation 4 changed to 3 or 2, or
Fontaine classiﬁcation changed from 3 to 2
Much improved Fontaine classiﬁcation 3 or 4 changed into no
more symptoms of PAD
Global rating of change according to Fontaine
classiﬁcation
Worse Unchanged Improved Much improved
Mean change in VascuQol sumscore (SD)
Baseline-6 months follow-up
0.03 (0.77) 0.34 (1.01) 0.69 (1.13) 1.59 (1.29)
MID 0.37 þ0.35
Number of patients changed in Fontaine
classiﬁcation
7 17 48 55
184 F.A. Frans et al.deviation is at least clinically signiﬁcant, but that smaller
values could also be clinically signiﬁcant.14,15 Determina-
tion of the MID enabled us to better express the propor-
tion of patients who clinically beneﬁtted or deteriorated
after treatment.
Our results suggest a plausible range within which the
MID for the VascuQol in patients treated for CLI could
probably fall. This information is useful in interpreting the
changes after treatment in other cohorts of patients with
CLI using VascuQol. However, one has to keep in mind that
the MID may vary among populations and that a single MID
may be insufﬁcient for all study applications involving PRO
measures.11 In the study by Nordanstig et al., who recorded
the VascuQol in 200 patients treated for PAD (65% IC, 35%Figure 2. Proportion of patients showing anCLI), the MID determined by the distribution-based
approach was 0.58, resulting in 72% of patients with a
clinically important beneﬁt.16 The difference in MID with
our study could be explained by differences in case-mix. The
anchor-based approach was not possible in the Nordanstig
study because they did not record a clinically relevant an-
chor.16 It is necessary to gain more experience with the
concept of a MID, that can also be applied to other PRO
measures for PAD in different patient cohorts and in
different and cross-cultural hospital settings. Furthermore,
the MID will also be useful in the planning of new studies,
as sample size calculations can be better based on the
magnitude of an expected difference that patients and in-
vestigators consider clinically important.(un) important beneﬁt or deterioration.
Fontaine classiﬁcation for peripheral arterial disease
Stage 1 No symptoms
Stage 2 Extremity muscle pain induced by exercise and
relieved by a short period of rest
Stage 3 Nocturnal and/or resting pain
Stage 4 Necrosis (death of tissue) and/or gangrene in the
limb
Change in Fontaine classiﬁcation
Worse Fontaine classiﬁcation changed from
3 to 4, or patients with Fontaine 4 developed
more ulcers or gangrene
Unchanged Fontaine classiﬁcation did not change
and for patients with Fontaine 4, number of
ulcers did not change
Improved Fontaine classiﬁcation 4 changed to 3 or 2, or
Fontaine classiﬁcation changed from 3 to 2.
Much
improved
Fontaine classiﬁcation 3 or 4
changed into no more symptoms of PAD
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 2 p. 180e186 February/2014 185In daily clinical practice, knowledge of a MID can help
clinicians to assess the perceived beneﬁt of a certain treat-
ment based on individual patient improvement. Patients can
be informed on the likelihood of important beneﬁt or
deterioration after a speciﬁc treatment. Finally, there is a
growing interest in using PROMS as benchmark for quality of
care. At this stage, it is important to know whether differ-
ences in quality of life are indeed relevant to the patient.
We realize that our study has limitations. We have to
consider selection bias. Selection bias limits the external val-
idity of our ﬁndings and could have considerable inﬂuence on
the precision of theMID. Furthermore, it indicates that the use
of patient reported outcomes in research and clinical practice
may be hampered by the frailty of CLI patients The excluded
frail CLI patientsmight have a lower baseline Qol than patients
with complete follow-up assessments. One might also argue
that someof the physiologicmetrics donotﬁt a CLI cohort.This
may in part be explained by inclusion of diabetics with high
ankle pressures causedbymedia calciﬁcation. In thesepatients
CLI was conﬁrmed by toe pressure measurement. The pres-
ence of CLI is further substantiated by the fact that themajority
of the included patients could not bemanaged conservatively.
It is preferable to determine the MID by means of both
patient-based, such as a global rating of change question,
and clinical anchors. Unfortunately, we could use only a
clinical anchor as we did not record a relevant patient-
based anchor when we designed the study. This is a ma-
jor limitation. It could have been interesting to ask a “global
rating of change question”, such as whether the patient
rates his status as deteriorated, unchanged or improved, or
with more subcategories.17 One could also relate the
changes in Qol to other instruments using the health
transition item (part of the Short Form-36)18 as a patient-
based anchor. Yet, the clinical anchor in our study com-
plied not only with the recommendations of Revicki et al. (a
correlation r .30 with the PRO instrument),11 but also with
the more stringent recommendations of Turner et al. (cor-
relation 0.5 between anchor and PRO change scores).19
This adds to the belief that the clinical anchor was appro-
priate. Furthermore, the sample size of 127 patients was
relatively small and as a result of this small sample, only
seven patients were in the clinical anchor category “worse”.
We are aware that formally we had to exclude this MID
estimate for “worse”, as we failed to meet the a priori cri-
terion of at least 10 subjects in each adjacent, clinically
distinct anchor category.15 However, we have performed
this study to explain the MID concept applied in PAD for the
ﬁrst time and to avoid confusion we choose to still mention
this MID estimate. Data on measurement precision of a Qol
instrument are needed to determine true differences in
scores. Precision can be determined by recording test-retest
reliability in patients with an unchanged disease status.
Although test-retest studies have been done for the Vas-
cuQol, these expressed the reliability as intraclass correla-
tion coefﬁcients. There are no data on systematic
differences between VascuQol results on different occa-
sions. These data are important to distinguish between true
effects or natural variation in measurement.CONCLUSION
PRO measures show the patients’ perspective on the impact
of disease and treatment. Although PRO measures are
frequently applied in patients with PAD, no previous study
has applied the concept of MID in such patients to deﬁne
clinically important changes rather than statistically signiﬁ-
cant changes in Qol. In this study we showed how an MID
can be assessed using both anchor and distribution-based
approaches. Although the traditional approach showed
that in patients with CLI, on average, the Qol signiﬁcantly
improved, the MID approach showed that on an individual
level 60% to 68% of the patients showed an important
beneﬁt. We hope that our study will result in more research
on the assessment of the MID for different PRO measures in
patients with PAD, as expression of changes in Qol by
means of the MID seems to provide better insight into
clinically important changes than statistical signiﬁcance.
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